MDxHealth Valuation
Is MDXHB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MDXHB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MDXHB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MDXHB's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MDXHB?
Key metric: As MDXHB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is MDXHB's PS Ratio? | |
|---|---|
| PS Ratio | 1.4x |
| Sales | US$63.69m |
| Market Cap | US$89.84m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | -4.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MDXHB's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.4x | ||
AREC Arecor Therapeutics | 5.9x | 35.2% | UK£28.9m |
TRX Tissue Regenix Group | 1.6x | 15.1% | UK£40.6m |
AVCT Avacta Group | 7.8x | 0.4% | UK£175.6m |
BVXP Bioventix | 14.4x | n/a | UK£195.7m |
MDXHB MDxHealth | 1.4x | 15.6% | €82.4m |
Price-To-Sales vs Peers: MDXHB is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (9.9x).
Price to Sales Ratio vs Industry
How does MDXHB's PS Ratio compare vs other companies in the GB Biotechs Industry?
Price-To-Sales vs Industry: MDXHB is good value based on its Price-To-Sales Ratio (1.4x) compared to the UK Biotechs industry average (16.7x).
Price to Sales Ratio vs Fair Ratio
What is MDXHB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate MDXHB's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
hVIVO
UK£134.7m
Operates as a pharmaceutical service and contract research company in the United Kingdom.
HVO
UK£0.20
7D
-16.8%
1Y
2.1%
Formycon
€844.9m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€48.35
7D
2.8%
1Y
-24.9%
Regeneron Pharmaceuticals
US$80.6b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$750.19
7D
0.5%
1Y
-5.7%